Back to top

PTC Therapeutics, Inc. (PTCT) Worth Watching: Stock Surges 10.4%
January 20, 2014

Read MoreHide Full Article

PTC Therapeutics, Inc. (PTCT - Free Report) was a big mover last session, as the company saw its shares a rise a little over 10% on the day. This surge can be attributable to solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up 55.7% in the past one-month time frame.

In the last 30 days, the company did not witness any estimate revisions and the Zacks Consensus Estimate has hit a plateau. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.

PTC Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked med drug stocks include DepoMed Inc. , Endocyte, Inc. (ECYT - Free Report) ) and Lannett Company, Inc. (LCI - Free Report) . All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

PTC Therapeutics, Inc. (PTCT) - free report >>

Lannett Co Inc (LCI) - free report >>

Endocyte, Inc. (ECYT) - free report >>

More from Zacks Tale of the Tape

You May Like